- Home
- RENB vs IPSC Comparison
RENB vs IPSC Comparison
Compare RENB & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- IPSC
- Stock Information
- Founded
- RENB 2011
- IPSC 2019
- Country
- RENB United States
- IPSC United States
- Employees
- RENB N/A
- IPSC N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- RENB Health Care
- IPSC Health Care
- Exchange
- RENB Nasdaq
- IPSC Nasdaq
- Market Cap
- RENB 61.0M
- IPSC 58.1M
- IPO Year
- RENB N/A
- IPSC 2021
- Fundamental
- Price
- RENB $0.32
- IPSC $0.54
- Analyst Decision
- RENB
- IPSC Strong Buy
- Analyst Count
- RENB 0
- IPSC 5
- Target Price
- RENB N/A
- IPSC $3.67
- AVG Volume (30 Days)
- RENB 683.6K
- IPSC 719.6K
- Earning Date
- RENB 05-19-2025
- IPSC 05-20-2025
- Dividend Yield
- RENB N/A
- IPSC N/A
- EPS Growth
- RENB N/A
- IPSC N/A
- EPS
- RENB N/A
- IPSC N/A
- Revenue
- RENB N/A
- IPSC $6,589,000.00
- Revenue This Year
- RENB N/A
- IPSC $833.10
- Revenue Next Year
- RENB N/A
- IPSC N/A
- P/E Ratio
- RENB N/A
- IPSC N/A
- Revenue Growth
- RENB N/A
- IPSC 194.81
- 52 Week Low
- RENB $0.29
- IPSC $0.34
- 52 Week High
- RENB $2.34
- IPSC $3.47
- Technical
- Relative Strength Index (RSI)
- RENB 37.38
- IPSC 51.91
- Support Level
- RENB $0.29
- IPSC $0.52
- Resistance Level
- RENB $0.35
- IPSC $0.57
- Average True Range (ATR)
- RENB 0.05
- IPSC 0.03
- MACD
- RENB 0.01
- IPSC 0.00
- Stochastic Oscillator
- RENB 18.83
- IPSC 58.75
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.